Although we did not show beneficial effects on survival with palbociclib plus Zol, CDK4/6 inhibitor and Zol combination therapy may still prove to be a suitable approach in treatment of metastatic TNBC, in order to prevent development of cancer-induced bone disease and associated skeletal-related events. Here, CDK4 is linked to cancer.